5fhx - Revision history

OCA at 06:51, 19 July 2023

OCA — Wed, 19 Jul 2023 06:51:41 GMT

←Older revision		Revision as of 06:51, 19 July 2023
Line 1:		Line 1:

	==CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION.==		==CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION.==
-	<StructureSection load='5fhx' size='340' side='right' caption='[[5fhx]], [[Resolution\|resolution]] 2.55Å' scene=''>	+	<StructureSection load='5fhx' size='340' side='right'caption='[[5fhx]], [[Resolution\|resolution]] 2.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5fhx]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FHX OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5FHX FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5fhx]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FHX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5FHX FirstGlance]. <br>
-	</td></tr><tr id='~~ligand~~'><td class="sblockLbl"><b>[[~~Ligand~~\|~~Ligands~~:]]</b></td><td class="sblockDat"~~><scene name~~=~~'pdbligand=PO4:PHOSPHATE+ION'>PO4</scene~~></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.55Å</td></tr>
-	<tr id='~~gene~~'><td class="sblockLbl"><b>[[~~Gene~~\|~~Gene~~:]]</b></td><td class="sblockDat">~~IL4 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode~~=~~Info&srchmode~~=~~5&id=9606 HUMAN])~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5fhx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fhx OCA], [~~http~~://pdbe.org/5fhx PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5fhx RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5fhx PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5fhx ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5fhx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fhx OCA], [https://pdbe.org/5fhx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5fhx RCSB], [https://www.ebi.ac.uk/pdbsum/5fhx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5fhx ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/IL4_HUMAN IL4_HUMAN]] Genetic variations in IL4 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:[~~http~~://omim.org/entry/601367 601367]]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.<ref>PMID:14681304</ref>	+	[https://www.uniprot.org/uniprot/IL4_HUMAN IL4_HUMAN] Genetic variations in IL4 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:[https://omim.org/entry/601367 601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.<ref>PMID:14681304</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/IL4_HUMAN IL4_HUMAN]] Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes.	+	[https://www.uniprot.org/uniprot/IL4_HUMAN IL4_HUMAN] Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 24:
	==See Also==		==See Also==
	*[[Antibody 3D structures\|Antibody 3D structures]]		*[[Antibody 3D structures\|Antibody 3D structures]]
		+	*[[Interleukin 3D structures\|Interleukin 3D structures]]
		+	*[[3D structures of human antibody\|3D structures of human antibody]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: ~~Dupuy, A~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Rak,~~ A]]	+	[[Category: Dupuy A]]
-	[[Category: ~~Vallee, F~~]]	+	[[Category: Rak A]]
-	[[Category: ~~Codv]]~~	+	[[Category: Vallee F]]
-	~~[[Category: Cross-over dual variable immunoglobulin multifunctional biotherapeutic drug]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 06:21, 24 October 2018

OCA — Wed, 24 Oct 2018 06:21:46 GMT

←Older revision		Revision as of 06:21, 24 October 2018
Line 3:		Line 3:
	<StructureSection load='5fhx' size='340' side='right' caption='[[5fhx]], [[Resolution\|resolution]] 2.55Å' scene=''>		<StructureSection load='5fhx' size='340' side='right' caption='[[5fhx]], [[Resolution\|resolution]] 2.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5fhx]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FHX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FHX FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5fhx]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FHX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FHX FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5fhx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fhx OCA], [http://pdbe.org/5fhx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fhx RCSB], [http://www.ebi.ac.uk/pdbsum/5fhx PDBsum]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IL4 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5fhx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fhx OCA], [http://pdbe.org/5fhx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fhx RCSB], [http://www.ebi.ac.uk/pdbsum/5fhx PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5fhx ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 5fhx" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5fhx" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Dupuy, A]]		[[Category: Dupuy, A]]
	[[Category: Rak, A]]		[[Category: Rak, A]]

OCA at 16:26, 10 May 2016

OCA — Tue, 10 May 2016 16:26:38 GMT

←Older revision		Revision as of 16:26, 10 May 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5fhx is ~~ON HOLD~~	+	==CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION.==
		+	<StructureSection load='5fhx' size='340' side='right' caption='[[5fhx]], [[Resolution\|resolution]] 2.55Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5fhx]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FHX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FHX FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5fhx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fhx OCA], [http://pdbe.org/5fhx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fhx RCSB], [http://www.ebi.ac.uk/pdbsum/5fhx PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/IL4_HUMAN IL4_HUMAN]] Genetic variations in IL4 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:[http://omim.org/entry/601367 601367]]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.<ref>PMID:14681304</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/IL4_HUMAN IL4_HUMAN]] Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Bispecific immunoglobulins (Igs) typically contain at least two distinct variable domains (Fv) that bind to two different target proteins. They are conceived to facilitate clinical development of biotherapeutic agents for diseases where improved clinical outcome is obtained or expected by combination therapy compared to treatment by single agents. Almost all existing formats are linear in their concept and differ widely in drug-like and manufacture-related properties. To overcome their major limitations, we designed cross-over dual variable Ig-like proteins (CODV-Ig). Their design is akin to the design of circularly closed repeat architectures. Indeed, initial results showed that the traditional approach of utilizing (G4S)x linkers for biotherapeutics design does not identify functional CODV-Igs. Therefore, we applied an unprecedented molecular modeling strategy for linker design that consistently results in CODV-Igs with excellent biochemical and biophysical properties. CODV architecture results in a circular self-contained structure functioning as a self-supporting truss that maintains the parental antibody affinities for both antigens without positional effects. The format is universally suitable for therapeutic applications targeting both circulating and membrane-localized proteins. Due to the full functionality of the Fc domains, serum half-life extension as well as antibody- or complement-dependent cytotoxicity may support biological efficiency of CODV-Igs. We show that judicious choice in combination of epitopes and paratope orientations of bispecific biotherapeutics is anticipated to be critical for clinical outcome. Uniting the major advantages of alternative bispecific biotherapeutics, CODV-Igs are applicable in a wide range of disease areas for fast-track multi-parametric drug optimization.

-	~~Authors: Vallee~~, F., ~~Dupuy~~, A., ~~Rak~~, A.	+	CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.,Steinmetz A, Vallee F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, Rak A, Wonerow P, Kruip J, Mikol V, Rao E MAbs. 2016 Mar 16:1-12. PMID:26984268<ref>PMID:26984268</ref>

-	~~Description: CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2~~.~~55 Ang~~. ~~RESOLUTION~~.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[Category: Unreleased Structures]]~~	+	</div>
-	~~[[Category~~: ~~Rak, A]]~~	+	<div class="pdbe-citations 5fhx" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
	[[Category: Dupuy, A]]		[[Category: Dupuy, A]]
		+	[[Category: Rak, A]]
	[[Category: Vallee, F]]		[[Category: Vallee, F]]
		+	[[Category: Codv]]
		+	[[Category: Cross-over dual variable immunoglobulin multifunctional biotherapeutic drug]]
		+	[[Category: Immune system]]

OCA: Protected "5fhx" [edit=sysop:move=sysop]

OCA — Wed, 30 Dec 2015 17:59:15 GMT

Protected "5fhx" [edit=sysop:move=sysop]

←Older revision

Revision as of 17:59, 30 December 2015

OCA: New page: '''Unreleased structure''' The entry 5fhx is ON HOLD Authors: Vallee, F., Dupuy, A., Rak, A. Description: CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION. [[Categ...

OCA — Wed, 30 Dec 2015 17:59:14 GMT

New page: '''Unreleased structure''' The entry 5fhx is ON HOLD Authors: Vallee, F., Dupuy, A., Rak, A. Description: CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION. [[Categ...

New page

'''Unreleased structure'''

The entry 5fhx is ON HOLD

Authors: Vallee, F., Dupuy, A., Rak, A.

Description: CRYSTAL STRUCTURE OF CODV IN COMPLEX WITH IL4 AT 2.55 Ang. RESOLUTION.
[[Category: Unreleased Structures]]
[[Category: Rak, A]]
[[Category: Dupuy, A]]
[[Category: Vallee, F]]